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Abstract We investigated the effect of lipoprotein(a) (Lp(a)) on 
proliferation of human arterial smooth muscle cells (SMCs) and 
its mechanisms of action. Low density lipoprotein (LDL), Lp(a) 
and apolipoprotein(a) (apo(a)) significantly stimulated the prolif- 
eration of SMCs. Lp(a) and apo(a) reduced the amount of active 
transforming growth factor-~ (TGF-~) with the mink lung ep- 
ithelial cell bioassay, however LDL had no effect. Lp(a), but not 
apo(a), significantly stimulated the proliferation of SMCs even 
in the presence of a neutralizing antibody for TGF-~. Our results 
suggest that Lp(a) stimulates the proliferation of SMCs via 
apo(a)-induced inhibition of TGF-~ activation and stimulation of 
SMCs by the LDL-particle of Lp(a). 
Key wor&: Lipoprotein(a); Smooth muscle cell: Transforming 
growth factor-fl 
2. Materials and methods 
2.1. Cell culture 
SMCs were explanted from the medial ayer of nonatherogenic au- 
topsy specimens obtained from adult humans. SMCs were cultured in 
MCDB 107 medium (Kyokuto Pharmaceutical Industrial Co., Tokyo, 
Japan) supplemented with basic fibroblast growth factor (1 ng/ml, 
provided by Takeda Medical Industries, Osaka, Japan), epidermal 
growth factor (10 ng/ml, Becton Dickinson Labware, Bedford, MA), 
5% FBS (Gibco, Grand Island, NY), penicillin (100 U/roll, streptomy- 
cin (100/~g/ml) and amphotericin B (0.05/~g/ml) (basic medium) in a 
humidified atmosphere of 5% COJ95% air. SMCs from the third to 
sixth passage were used for experiments. The smooth muscle cell nature 
of the cultures was confirmed by microscopic identification of their 
characteristic 'hill-and-valley" growth pattern and by immunohisto- 
chemical identification of smooth muscle actin using a specific mono- 
clonal antibody (HHF35, Enzo Diagnostics, Syosset, NY). 
1. Introduction 
Lipoprotein(a) (Lp(a)) discovered by Berg in 1963 [l] is be- 
lieved to be a risk factor for coronary heart disease [2-6], vein 
graft stenosis after coronary artery bypass [7] and restenosis 
after percutaneous transluminal coronary angioplasty [8,9]. 
Lp(a) is an low density lipoprotein (LDL)-like particle with a 
characteristic polymorphic glycoprotein known as apolipopro- 
tein(a) (apo(a)) that is disulfide linked to the apolipoprotein B 
moiety of LDL [10]. The complementary DNA sequence of 
human apo(a) has been found to be homologous to human 
plasminogen [11]. Because Lp(a) contains both an LDL particle 
and apo(a), it is believed to have both proatherogenic and 
prothrombotic properties. However, the precise mechanisms by 
which Lp(a) promotes atherosclerosis have not been clarified. 
The proliferation and migration of vascular smooth muscle 
cells (SMCs) are major contributors to atherosclerosis and 
restenosis after angioplasty. Lp(a) is reported to enhance the 
migration [12] and proliferation [13] of cultured SMCs by re- 
ducing the level of transforming growth factor-fl (TGF-fl), 
which inhibits migration and proliferation of SMCs. The strik- 
ing homology between apo(a) and plasminogen suggests that 
Lp(a) inhibits plasmin-induced activation of TGF-fl by inhibit- 
ing plasminogen activation. A recent study suggests that activa- 
tion of TGF-f l  is inhibited in the aortic wall and in serum in 
transgenic apo(a) mice [14]. In the present study, we investi- 
gated the mechanisms of action in detail which Lp(a) stimulated 
the proliferation of SMCs. 
*Corresponding author. Fax: (811 (992t 65 8447. 
22. Lipoprolein-d~fieient serum 
Lipoprotein-deficient serum (LPDS/was prepared from FBS by the 
method of Chen et al. [15]. Briefly, FBS was adjusted to a density of 
1.21 g/ml with solid potassium bromide (KBr) and centrifuged at 
140,000 x g for 48 hours. After centrifugation, the upper fraction with 
a density below 1.21 g/ml was removed. The bottom fraction, referred 
to as LPDS, was dialyzed extensively against phosphate-buffered sa- 
line. 
2.3. Isolation oj Lp(a), apo(a), LDL and HDL 
Plasma was obtained from donors with elevated Lp(a) concentra- 
tions after 12 hours of fasting. Butylated hydroxytoluene (10 ,uM) was 
added during all procedures to avoid the oxidation of lipoproteins. 
Lp(a) was isolated according to the modified method ofAlbers et al. 
[16]. Briefly, the plasma was adjusted to a density of 1.060 g/ml with 
solid KBr and then centrifuged at 150,000 xg at 10°C for 24 h. The 
bottom fraction was readjusted to a density of 1.090 g/ml with solid 
KBr and recentrifuged at 150,000 x g for 26 hours. The resulting lipo- 
proteins with densities of 1.060 to 1.090 g/ml were subfractionated by
ascending el chromatography on6% agarose gel (Bio-Gel A-5m, 20~ 
4011 mesh. Bio-Rad Laboratories, Richmond, CA) at 18°C using a 
2.6 × 90 cm column at a flow rate of 12 ml/hour. The sample volume 
was 4 to 6 ml and the eluting buffer contained 0.1 M Tris-HCl, 0.15 M 
NaCI and 0.001 M EDTA (pH 8.2). Fractions were collected at 4 
ml/tube. The absorbance of the eluates was measured with an ultravio- 
let spectrophotometer at 280 nm. Appropriate fractions were pooled, 
concentrated with MINICON-B (Amicon, Beverly, MA) and then 
dialyzed with MCDB 107 medium. Plasma nd peak fractions of Lp(a), 
LDL and high density lipoprotein (HDL) were analyzed by Western 
blotting for apo(a) using an antibody against apo(a) (provided by 
Daiichi Pure Chemicals, Tokyo, Japan). 
Apo(a) was isolated by the method of Armstrong et al. [17]. Briefly, 
10 ~ M of dithiothreitol/mg of protein was added to purified Lp(a), and 
the solution was incubated at 37°C for 3 hours and then adjusted to 
a density of 1.063 g/ml with solid KBr. After centrifugation at 
150,000 x g t\~r 20 hours at 10°C, pellets sedimented atthe base of the 
tube were collected and dialyzed with MCDB107 medium. 
HDL (d 1.085 to 1.210 g/roll and LDL (d 1.010 to 1.063 g/roll were 
isolated from plasma by the method of Havel et al. using KBr and 
ultracentrifugation [18]. 
The protein content was determined by BCA protein assay reagent 
(Pierce. Rockford, ILl. 
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2.4. Prol(/eration assay 
We determined SMC proliferation by counting cells with a Coulter 
counter (Coulter Electronics, Luton, England) and measuring [~H]thy- 
midine incorporation i SMCs as described previously [19]. 
2.5. TGF-fl bioassay 
To prepare conditioned medium, human arterial SMCs were tirst 
cultured in the control medium (1% LPDS) for 24 hours. The control 
medium was then removed and attached SMCs were rinsed and incu- 
bated with DME (Gibco, Grand Island, NY) alone for 24 hours. To 
determine the total amount of latent and active TGF-]/, the conditioned 
medium was acidified to pH 2.0 with 1N HCI and after 1 hour at 4°C 
was neutralised to pH 7.5 with 1 N NaOH. TGF-fl activity in condi- 
tioned medium of human arterial SMCs was confirmed by the method 
of Gangrade t al. [20] using mink lung epithelial cells (kindly provided 
by Dr. Y. Sato, Oita Medical University. Oita, Japan). Mink lung 
epithelial cells (500,000 cells/cm -~1 were cultured in 24-well dishes in 
DME containing 5% FBS in triplicate in the presence or absence of 
various concentrations of conditioned medium or TGF-fl] (King Brew- 
ing, Kanagawa, Japan) and incubated at 37°C in a humidified gas (95% 
air, 5% CO~) chamber. The conditioned medium was removed after 24 
hours and [~H]thymidine (1/ICi/ml) was added to cultures for 4 hours. 
Incorporation of[3H]thymidine in the DNA of mink lung epithelial cells 
was determined with a liquid scintillation counter (TRI-CARB 4430, 
Packard Instrument, Downers Grove, IL). Standard curves for TGF-fl 
were established by logit-log transformation f [3H]thymidine incorpo- 
ration as a function of the TGF-]/dose (10 to 1000 pg/ml). This pro- 
duced a linear plot from which the content of TGF-fl in experimental 
samples was calculated. 
Neutralizing mouse monoclonal antibody against TGF-¢/,, fl~,/:t~ was 
purchased from Genzyme (Cambridge. MA). 
2.6. Statistical analysi~s 
Data are presented as the mean -+ S.D. Differences of mean values 
between groups were analyzed by the unpaired Student's t-test. Proba- 
bility values of less than 0.05 were considered statistically significant. 
3. Results 
3.1. Iso&tion q/Lp(ae 
The elution profile of l ipoprotein fractions with densities of 
d 1.060 to 1.090 g/ml showed three peaks (Fig. 1). Western blot 
analysis of serum and the three peak fractions identified apo(a) 
bands in serum and the Lp(a) fraction (Fig. l). 
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Fig. 1. Elution profile of a representative 1.061t to 1.090 g/ml lipoprotein 
fraction separated on Bio-Gel A-5m. Three elution peaks were ob- 
served: Lp(a), LDL and HDL. Insert: Western blot analysis. Serum and 
the Lp(a) fraction showed apo(a) bands. Lane A: serum, lane B: peak 
fraction of HDL, lane C: peak fraction of LDL, lane D: peak fraction 
of Lpla). 
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Fig. 2. Proliferation of SMCs incubated with Lp(a), LDL or HDL. 
A: Dose response curve of growth of SMCs incubated with Lp(a), LDL 
or HDL. SMCs were cultured in MCDB 107 medium supplemented 
with basic fibroblast growth factor (1 ng/ml), epidermal growth factor 
(10 ng/ml), 1% LPDS and the indicated amounts of lipoproteins. 
B: Time course of growth of SMCs incubated with Lp(a) or LDL. 
Closed triangles indicate control medium (1% LPDS), closed circles 
indicate control medium plus Lp(a) (80/tg/ml protein) and closed 
squares indicate control medium plus LDL (80/zg/ml protein). SMCs 
were counted on Day 3 and Day 5. Values are the mean + S.D. in a 
representative experiment of triplicate samples. 
3.2. L~/bct o [Lp(a j  on SMC proliJeration 
Dose-response curves showed that Lp(a) and LDL increased 
[~H]thymidine incorporat ion in SMCs in a dose-dependent 
manner  (Fig. 2A). HDL  caused less incorporat ion of [3H]thy- 
midine in SMCs. The number  of SMCs incubated with Lp(a) 
(80/~g/ml protein) or LDL (80/~g/ml protein) increased with 
time (Fig. 2B). The number of SMCs was significantly higher 
on Day 5 in the LDL- and Lp(a)-containing media compared 
with the control medium in the six experiments of triplicate 
samples (control: 6905+768,  Lp(a): 9416+ 1570, LDL: 
11702 _+ 1303; LDL vs. control: P< 0.01, Lp(a) vs. control: 
P < 0.05). 
3.3 TGF-fl bioassay 
Both Lp(a) and apo(a) reduced the concentrat ion of active 
TGF-f l  compared with the control medium. LDL had no effect 
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Table 1 
Amount of active TGF-/~ 
TG F-,B (ng/ml) 
Control 0.5 + 0.1 
Lp(a) (80/~g/ml protein) <0.1 
apo(a) (40 ktg/ml protein) <0.l 
LDL (80/lg/ml protein) 0.5 _+ 0.1 
Neutralizing antibody for TGF-]~ <0.1 
Values represent the mean _+ S.D. of the amount of active TGF-/~ of 
two experiments with triplicate samples. 
on the TGF-fl level. The total amount of latent and active 
TGF-]~ in the control medium was 1.4 + 0.1 ng/ml. In the me- 
dium with a neutralizing antibody for TGF-/~, active TGF-fl 
was less than 0.1ng/ml (Table 1). 
3.4. Efjeet of Lp(a) and apo(a) on SMC proliJeration 0l the 
presence of neutralizing antibody.liar TGF-t~ 
To determine whether Lp(a) stimulated SMC proliferation 
only by inhibiting activation of TGF-fl, we assayed SMC prolif- 
eration in the presence or absence of a neutralizing antibody 
for TGF-fl (Ab). We used enough amount of the neutralizing 
antibody for TGF-fl which can neutralize 1.0 ng/ml of active 
TGF-fl, because the concentration of active TGF-fl in control 
was 0.5 +_ 0.1 ng/ml. We confirmed that the antibody effectively 
neutralized the active TGF-]~ by TGF-/~ bioassay (Table 1). 
Incorporation of [3H]thymidine was significantly higher in 
SMCs incubated with the neutralizing antibody for TGF-fl 
(Ab) than in SMCs incubated with IgG (IgG: 1331 _+ 183 CPM, 
Ab: 2126 _+ 248 CPM; P < 0.05) (Fig. 3A). Incorporation of 
[3H]thymidine was also significantly higher in SMCs incubated 
with Ab plus Lp(a) (80/zg/ml protein) than in SMCs incubated 
with Ab alone (Ab: 2126 + 248 CPM, Ab + Lp(a): 2966 + 227 
CPM; P < 0.05) (Fig. 3A). Apo(al (40/~g/ml protein/ signifi- 
cantly increased [~H]thymidine incorporation compared with 
IgG (IgG: 1416 + 65 CPM, IgG + apo(a): 1900 _+ 100 CPM: 
P < 0.01) (Fig. 3B). However. in contrast o Lp(a), apo(a) did 
not significantly increase [3H]thymidine incorporation i SMCs 
in the presence of Ab (Ab: 2107 + 113 CPM, Ab + apo(a): 
2126 + 128 CPM: not significant) (Fig. 3B). 
4. Discussion 
An elevated Lp(a) level is a risk factor for coronary heart 
disease [2 6], stenosis of saphenous vein graft [7] and restenosis 
after angioplasty [8,9]. Immunohistochemical staining with a 
specific antibody to apo(a) has shown a substantial mount of 
Lp(a) in human aortic atherosclerotic plaques [21]. Lipid-stain- 
ing lesions in the aorta and co-localization of apo(a) with lipid 
deposition in the arterial wall have been observed in transgenic 
mice expressing human apo(a) [22]. Possible mechanisms of" 
Lp(a)'s involvement in atherosclerosis include inhibition of fi- 
brinolysis [23 25], stimulation of proliferation [13] and migra- 
tion [14] of SMCs, uptake of Lp(a) glycosaminoglycan com- 
plex by macrophages [26], and the formation of an insoluble 
LDL Lp(a) complex in the presence of calcium ions [27]. Stud- 
ies have suggested that Lp(a) may promote thrombotic events 
by interfering with the fibrinolytic functions of plasminogen 
and/or plasmin [23 25] because the complementary DNA 
495 
sequence of human apo(a) is homologous to human plasmino- 
gen [11]. 
SMC migration and proliferation are believed to be key con- 
tributors to the development of spontaneous atherosclerosis 
and restenosis after angioplasty. Kojima et al. suggested that 
high concentrations of Lp(a) may enhance SMC migration by 
reducing the level of TGF-fl, which inhibits migration of SMCs 
[12]. Grainger et al. reported that Lp(a) and apo(a) stimulated 
the growth of human SMCs by inhibiting plasminogen activa- 
tion, leading to inhibition of plasmin-induced activation of la- 
tent TGF-//, an inhibitor of SMC growth [13]. In the present 
study, we also found that Lp(a) and apo(a) stimulated prolifer- 
ation of cultured human arterial SMCs. Lp(a) and apo(a) re- 
duced the amount of active TGF-fl. These results uggest hat 
Lp(a) and apo(a) stimulated growth of SMCs by inhibiting 
activation of TGF-fl. To determine whether inhibition of TGF- 
//activation was the sole mechanism of Lp(a)-induced stimula- 
tion of SMCs, we assessed the effect of Lp(a) on growth of 
SMCs in the presence or absence of a neutralizing antibody for 
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Fig. 3. Effect of kp(a) or apo(a) on SMC proliferation i the presence 
or absence of a neutralizing antibody for TGF-fl (Ab). A: Incorporation 
of [3H]thymidine was measured in SMCs incubated with IgG, IgG plus 
Lp(a) (80/zg/ml protein), Ab alone or Ab plus Lp(a) (80,ug/ml protein). 
B: Incorporation of [3H]thymidine was measured in SMCs incubated 
with lgG, IgG plus apo(a) (40/zg/mf protein), neutralizing antibody for 
TGF-]~ (Ab) or Ab plus apo(a) (40 ~g/ml protein). Values are the 
mean + S.D. of the three experiments of triplicate samples. NS: not 
significant. 
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TGF-fl, which abolished the effect of TGF-fl. In the presence 
of the neutralizing antibody for TGF-fl, Lp(a), but not apo(a), 
stimulated SMC growth, suggesting that LDL-particle of Lp(a) 
may promote SMC proliferation. Our results uggest that Lp(a) 
may stimulate proliferation of vascular SMCs through two 
pathways: apo(a)-induced inhibition of activation of TGF-fl 
and stimulation of SMCs by the LDL-particle of Lp(a). 
TGF-fl is a multifunctional peptide that controls prolifera- 
tion, differentiation a d other functions in many cell types [28]. 
TGF-fl is reported to inhibit growth of SMCs under some 
conditions [29-31] and to stimulate growth under other condi- 
tions [32]. In the present study, exogenous TGF-fl (0.5 to 1.0 
ng/ml) inhibited SMC growth in the control medium (data not 
shown) and [3H]thymidine incorporation was significantly 
higher in SMCs incubated with the neutralizing antibody for 
TGF-fl than in SMCs incubated with IgG (Fig. 3A), confirming 
that TGF-/3 is a potent inhibitor of the growth of SMCs. 
Some studies have shown that LDL stimulates SMC growth 
[15,33 35], but others have found no evidence of LDL-induced 
stimulation [13,36]. These disagreements may reflect differences 
either in the assay conditions or in the modification of LDL 
employed in various studies. In the present study, we cultured 
cells in a medium containing LPDS to clarify the role of lipo- 
proteins in growth of SMCs and we obtained lipoproteins using 
butylated hydroxytoluene to avoid their oxidation. In our ex- 
perimental system, LDL stimulated proliferation of SMCs. 
Lp(a), but not apo(a), stimulated SMC growth even in the 
presence of the neutralizing antibody for TGF-fl, suggesting 
that this mitogenic effect may be related to the LDL-like action 
of Lp(a). 
In conclusion, our results suggest that Lp(a) stimulates the 
proliferation of SMC through two pathways: apo(a)-induced 
inhibition of TGF-fl activation and stimulation ofSMCs by the 
LDL-particle of Lp(a). 
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